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INTRODUCTION
Cystic fibrosis-associated liver disease (CFLD) is characterized by indolent intrahepatic cholestasis that usually manifests by early adolescence 1 . Cystic fibrosis (CF) is caused by a defect in the gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) which, among other functions, maintains the flow of bile in contact with cholangiocytes by facilitating the movement of water and bicarbonate ions into bile.
Abnormal ion/water transport leads to inspissated bile and cholestasis with focal fibrosing destruction of intrahepatic bile ducts 2 . The resulting pattern of injury is focal biliary cirrhosis for which there is no known treatment and which may progress to cause portal hypertension, multilobular biliary cirrhosis and liver failure. However, only 10% of children with CF will develop portal hypertension and cirrhosis, a higher prevalence than the overall CF population, indicating a strong survival disadvantage. The cause and mechanism of this variable presentation and severity of pathology are not known 3 .
The Ductular Reaction (DR) is characterized by the expansion of a population of bipotential liver progenitor cells (LPCs) which can differentiate towards the cholangiocyte lineage into reactive bile ductules, as well as intermediate hepatocytes 4, 5 . LPCs have been proposed by some groups to reside within peri-portal areas associated with the Canals of Hering 6 , although their precise cellular origin is the subject of ongoing controversy 7 . LPC expansion is thought to mediate a secondary pathway of liver regeneration, which occurs when the process of hepatocyte replication is overwhelmed in chronic liver disease 8 . In cholestasis this expansion is postulated to be a futile attempt to drain excess bile via the formation of additional bile ductules and to replace damaged hepatocytes 9 . The DR is observed along with activation of hepatic stellate cells (HSCs) and an increase in hepatic fibrosis, which is seen in M A N U S C R I P T A C C E P T E D Bile acids are synthesized in hepatocytes from cholesterol and are usually conjugated to taurine or glycine to form bile salts and secreted into the bile canaliculi. These bile secretions flow into bile ducts, where they are stabilized by bicarbonate ions and water secreted by cholangiocytes as they are excreted from the liver into the gall bladder. They aid lipid digestion in the duodenum by forming micelles. However, their partial hydrophobic nature, which is essential in forming micelles, also makes them toxic to the liver in higher concentrations 18 . The bile salt composition within bile is altered in children with CFLD, as we have previously shown 19 , and is comparable to that of mice following bile duct ligation 20 . In particular, the hydrophobic bile salt, taurocholate is significantly increased in both bile and serum of children with CFLD 21 . Taurocholate and other bile salts are able to upregulate the expression of inflammatory genes in the liver 22 . Taurocholate has also been shown to stimulate cytokine secretion from cholangiocytes 23 and hepatocytes 21 , which induce transdifferentiation of portal fibroblasts 24 as well as facilitating HSC migration 21, 25 . We previously demonstrated that taurocholate induced the expression of monocyte chemotaxis protein-1 (MCP-1) in normal hepatocytes, and that MCP-1 produced by cholestatic hepatocytes from bile duct-ligated rats induced the chemotaxis of HSCs 21 . Markedly
increased expression of MCP-1 was observed in hepatocytes and cholangiocytes in the liver of children with cholestatic liver diseases 21 .
In this study we investigated whether the DR is present in the liver of children with CFLD and examined mechanisms associated with its induction and role in fibrogenesis. We compared the severity of the DR in CFLD liver biopsies with those from other, more aggressively cholestatic pediatric liver disease and then specifically examined a potential mechanism of DR induction in CFLD through investigating the relationship between biliary taurocholate concentrations and the DR in liver biopsies from children with CFLD in vivo.
We then used in vitro cell culture models and ex vivo liver slices to investigate the in vivo observed effects of elevated taurocholate on LPC differentiation, the secretion of chemokines by LPCs and their chemotactic effects on HSCs in driving hepatic fibrogenesis.
MATERIALS AND METHODS
Patient specimens. This study is part of a long-term prospective cohort study of patients with CFLD identified and referred from the CF Clinic, Royal Children's Hospital, Brisbane, previously well documented 19, 21, [26] [27] [28] . CFLD was defined as two of the following: (i) hepatomegaly ± splenomegaly; (ii) persistent (>6mo) elevation of serum alanine aminotransferase (>1.5x upper limit normal); and (iii) abnormal liver ultrasound (abnormal echogenicity or nodular edge). Those with liver synthetic dysfunction or a history of hepatobiliary surgery were excluded. The study conformed to the ethical guidelines of the M A N U S C R I P T Biliary taurocholate measurement. Taurocholate concentration was measured in endoscopic bile samples available from seven patients with CFLD, as previously described 21 .
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Liver biopsies were processed for histochemical CK7 quantification as above. All patients had histological evidence of hepatic fibrosis. Biliary taurocholate levels were correlated with CK7 quantification.
Culture of cell lines and in vitro studies. The murine LPC line PIL-2 29 was cultured in
Williams' E medium containing 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml), insulin (10 µg/ml), epidermal growth factor (10 ng/ml), insulin-like growth factor II (30 ng/ml) and 10% fetal bovine serum (FBS). The human HSC line LX-2 was cultured in DMEM with 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 2% FBS. RT-qPCR for LPC differentiation marker and chemokine mRNA expression. RNA was extracted from both untreated and taurocholate-treated PIL-2 cells using the RNeasy kit (Qiagen) and 1µg was reverse-transcribed into cDNA using SensiFast (Bioline). Real-time qPCR was performed on a Biorad CFX96 with HPRT used as the reference gene. Primers are listed in Table 1 .
MTT cell proliferation assay. Cell proliferation was measured over a two hour period at 1-4 days following treatment of PIL-2 cells with 150µM sodium taurocholate using the method of Alley et al. 30 . Absorbance was measured at 570nm with a 620nm reference filter.
Western blot analysis.
Cell lysates were prepared from PIL-2 cells disrupted in RIPA buffer with Complete EDTAfree protease inhibitors (Roche). Lysates were resolved on 10% SDS-PAGE gels as described in Laemmli et al. 31 Immunofluorescence. To examine primary cilia, PIL-2 cells were grown on glass coverslips to 60-80% confluence and treated for three days ± 150µM taurocholate and serum-starved overnight prior to fixation. Cells were placed at 4°C for 30 minutes to destabilize microtubules and then fixed in 4% paraformaldehyde for 10 minutes. Cells were permeabilized with 0.5% Triton X-100, blocked with 5% BSA and probed with mouse anti- Gold (Invitrogen) with DAPI and examined by confocal microscopy (Zeiss 780NLO).
Ex vivo liver slice studies. Precision-cut liver slices were performed as previously described 32 . A minimum of three liver slices each from three separate C57BL6 WT mice for each time point and each treatment group, were incubated in Williams' E medium containing 2mM glutamine, penicillin (100 U/ml), streptomycin (100 µg/ml) and 10% FBS at 37°C for two and four days ± 150µM taurocholate. Conditioned medium was examined for GGT enzyme activity. Slices were harvested for mRNA quantitation using RT-qPCR. γ γ γ γ-Glutamyl Transpeptidase Activity Assay. GGT activity was determined from in vitro cell cultures and ex vivo liver slice conditioned media using the GGT activity colorimetric assay kit (Sigma-Aldrich). Protein for normalization was measured using the Pierce BCA protein assay (Thermo Fisher Scientific). (Figure 3A ; ANOVA, p<0.0001) and Ck19 ( Figure 3B; ANOVA, p<0.0001). A taurocholate concentration of 150µM was chosen for all subsequent experiments as has previously been described in in vitro studies 21, 23 , and also being consistent with previous observations in children with CFLD that displayed a mean biliary taurocholate concentration of 108µM vs 41µM in healthy controls 21 .
Quantification of cytokine protein secretion from
PIL-2 cells were treated with 150µM taurocholate for 0-4 days and markers of cholangiocyte differentiation were further assessed. Taurocholate induced a time-dependent increase in mRNA expression of cholangiocyte markers Cx43 (Figure 3C ; ANOVA p<0.0001), Ck19 Thus, we examined expression of proteins involved in various aspects of biliary cell function.
We observed that CK19, a protein responsible for the structural integrity of cholangiocytes is significantly induced by taurocholate (Figure 6A and B; p=0.0006). Taurocholate also induced a significant >2.5-fold increase in SOX9 protein, a key transcriptional regulator of cholangiocyte differentiation and bile duct formation (Figures 6A and C; p=0.001).
Conversely, HNF4α protein expression, a marker and transcriptional regulator of hepatocyte specification, was significantly decreased by taurocholate (Figures 6A and D; p=0.019).
One key morphological characteristic of cholangiocytes is the presence of primary cilia with 
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Another measure of functional LPC-cholangiocyte differentiation is the production of enzymatically active GGT, which is expressed and released by cholangiocytes within bile ducts. PIL-2 cells were treated ± 150µM taurocholate for 1-4 days with conditioned medium removed for analysis every 24hrs. Taurocholate induced a significant time-dependent increase in GGT activity (ANOVA, p<0.0001), with maximal production between days 3-4
( Figure 7C) . At the conclusion of the experiment (day 4), this result remained highly significant when corrected for cellular protein concentration (Supplementary Figure S1) .
The effect of taurocholate in ex vivo precision-cut liver slices. To demonstrate potential physiological relevance of our in vitro observation, we used precision-cut liver slices from normal control mice, treated ± 150µM taurocholate for up to four days. The hepatic mRNA expression of Cx43, as a representative cholangiocyte marker, was significantly increased in a time-dependent manner ( Figure 8A ; ANOVA, p=0.0354). Conditioned medium collected was assayed for GGT activity and normalized to liver slice wet weight. Taurocholate again induced a significant increase in GGT activity, peaking at day 2 ( Figure 8B ; ANOVA, p=0.0021).
Chemokine expression induced by taurocholate in LPCs. PIL-2 cells treated with 150µM
taurocholate showed significantly increased expression of MCP-1, MIP1α, and RANTES mRNA at 6hrs ( Figure 9A) . We also examined the gene expression of the profibrotic cytokine TGF-β1 and HSC mitogen PDGFB, which both have HSC chemotactic potential.
While taurocholate induced increased expression of both TGF-β1 and PDGFB, this did not reach statistical significance ( Figure 9A ). Figure 9B) . Taurocholate induced an increase in MCP-1 secretion, however this did not reach statistical significance. By 24hrs, chemokine levels were indistinguishable from controls, except for PDGFB, which remained elevated in response to taurocholate (p<0.05). No effect was observed on TGF-β1 release.
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HSCs migrate in response to chemokines secreted by taurocholate-treated LPCs.
Chemotaxis of the LX-2 HSC line was significantly induced by conditioned medium from PIL-2 cells treated with taurocholate for either 6hrs (p<0.001) or 24hrs (p<0.01) ( Figure   10A ). Similar levels of chemotaxis were demonstrated using primary rat HSCs (data not shown). To determine the identity of chemokines responsible for this chemotaxis, conditioned medium was pre-treated with neutralizing antibodies to various different chemokines. Chemotaxis was completely inhibited by anti-MIP1α neutralizing antibody (nAb), however, anti-RANTES nAb had no effect ( Figure 10B ). While chemotaxis of LX-2 cells was partially suppressed using anti-MCP-1 nAb, this did not reach statistical significance. ( Figure 13A and B) .
HSCs migrate in response to
DISCUSSION
The DR is proposed to be associated with the initiation of hepatic fibrosis in a number of chronic liver diseases 4, 12, 34, 35 . However, the precise mechanisms involved in its induction and indeed in the interactions between LPCs and HSCs, which may drive both the DR and fibrogenesis, remain to be elucidated. This histological process has been reported in many M A N U S C R I P T
A C C E P T E D ACCEPTED MANUSCRIPT
18 adult liver diseases including chronic hepatitis C 12 , alcoholic and non-alcoholic steatohepatitis 14, 35 and genetic hemochromatosis 13 . In these diseases, the DR correlates closely with severity of fibrosis and inflammation 34 . However, the presence or role of the DR has not previously been investigated in children with CFLD. Here we show that the DR is indeed present in CFLD (and comparable to the DR present in more aggressive pediatric fibrosing cholestatic diseases such as biliary atresia 36, 37 ) and the extent of the DR significantly correlates with fibrosis staging in CFLD, suggesting that mechanisms regulating these two processes are interrelated.
Extensive investigation into the individual mechanisms of LPC and HSC activation 38 have elucidated a role for many different soluble mediators in hepatic fibrosis. Understanding the interaction between LPCs and HSCs is of great importance for clarifying the contribution of these cells in mediating fibrogenesis and for designing therapeutic strategies aimed at reduction of hepatic fibrosis.
Bile salt retention is part of the proposed mechanism of injury and biliary fibrosis in CFLD and we previously demonstrated that biliary/serum levels of the conjugated bile acid taurocholate are elevated in children with CFLD 21 . In the present study we demonstrated that the extent of the DR correlates with biliary taurocholate concentration in children with CFLD and thus speculate a potential mechanistic link. To determine whether taurocholate plays a role in inducing the DR, we used both an LPC in vitro cell culture model and ex vivo precision-cut liver slices, and employed a reductionist strategy to examine the impact of taurocholate on three key events in the evolution of the DR: LPC proliferation, biliary differentiation of LPCs and HSC chemotaxis.
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In this study, we demonstrated that taurocholate increased LPC proliferation in vitro, suggesting that taurocholate may play a role in enhancing LPC expansion as part of the DR in CFLD. This observation is supported by studies from Clouzeau-Girard et al. 39 showing that taurocholate leads to uncharacterized cell proliferation around the portal tracts in ex vivo liver slices. Our data are also consistent with the observation that feeding taurocholate to rats increases cholangiocyte numbers 40 , although this study did not distinguish whether these were mature adult cholangiocytes or derived from LPCs. have also suggested that membrane contact (and cross-talk) between LPCs and HSCs is a key mediator of fibrogenesis 41, 46, 47 . In this context, our previous work showed that HSCs treated with the TNF superfamily member, lymphotoxin-β, induces NFκB signalling, upregulating chemotaxis-associated factors such as RANTES and ICAM-1, aiding in LPC and inflammatory cell recruitment. As HSCs express the lymphotoxin-β receptor on their cell surface and lymphotoxin-β is a membrane-bound ligand on LPCs, this suggests that direct cell-cell contact between LPCs and HSCs may be required to initiate chemokine expression 41 . Adding to the complexity of this system, high concentrations of taurocholate have also been shown to induce inflammatory gene expression in hepatocytes as well as cytokine/chemokine secretion that may also lead to HSC recruitment and activation 21, 22 . The present study suggests that the DR precedes fibrosis. However, there is an alternate hypothesis stating that fibrosis precedes the DR and there is some evidence to support this in animal studies 48 . It is also possible that the two processes may be injury context-specific thus further investigations are warranted to fully elucidate the temporal nature of LPC niche development. In addition to HSCs, portal fibroblasts may also contribute to CFLD. However, while previous studies have shown that both activated HSCs and myofibroblasts produce collagen in this disease 26 , the role of myofibroblasts derived from portal fibroblasts and indeed the potential recruitment by, and interaction between, these cells and LPCs has not been previously investigated.
In conclusion, this study has shown that the DR is present in CFLD and is correlated with biliary taurocholate levels as well as increasing hepatic fibrosis severity. Thus, we propose that the following model may in part help to explain the pathogenesis of CFLD (Figure 14 ).
In this model, the CFTR defect causes thickened mucous secretions and obstruction of the intrahepatic bile ducts. This obstruction elevates biliary levels of bile salts such as 
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